She suffered from Sjogren syndrome and inflammatory arthritis and was currently treated with prednisone and methotrexate. She was previously treated with hydroxychloroquine (Plaquenil) 200mg bid (6.5mg/kg) for 10 years, which was stopped one year prior to presentation. Chloroquine phosphate solubility storage All well and plaquenil Chloroquine hek293 Plaquenil maculopathy dose The goal for Plaquenil Screening to detect toxicity early and stop the medication as soon as possible if present. Functional test that focus on central field sensitivity may pick up early toxicity. Early structural changes may be difficult to detect and high resolution optical coherence tomography OCT and fundus autofluorescence are very. Plaquenil prolongs the QT interval. Ventricular arrhythmias and torsades de pointes have been reported in patients taking Plaquenil see OVERDOSAGE. Therefore, Plaquenil should not be administered with other drugs that have the potential to prolong the QT interval see DRUG INTERACTIONS. Ophthalmologists currently screen for hydroxychloroquine retinopathy correctly, however, their lack of familiarity with evidence-based guidelines may result in excessive follow up. Increasing awareness and implementation of the PPP could potentially reduce hydroxychloroquine retinopathy screening costs significantly. Review of systems: Blurred vision, halos, dry eye, dry mouth, gastroesophageal reflux, joint pain Pupils: Reactive to light in each eye from 5 mm in the dark to 2 mm in the light. Extraocular movements: Full, both eyes (OU) Confrontation visual fields: Full OU Intra-ocular pressure The optic nerves appeared healthy with a 0.3 cup-to-disc ratio. Past Ocular History: None Medical History: Sjogren syndrome and inflammatory arthritis, supraventricular tachycardia, anxiety, depression, peptic ulcer disease Medications: prednisone, methotrexate, amitriptyline, ranitidine, estradiol, tizanidine, diltiazem, Restasis Allergies: codeine, droperidol Family History: heart disease, arthritis, cancer Social History: occasional alcohol but no tobacco or intravenous drug use. Plaquenil retinal screening interval New Plaquenil Guidelines, Plaquenil - FDA prescribing information, side effects and uses Hydroxychloroquine erectile dysfunction The subjective component to HCQ retinopathy screening is an automated visual field testing the central 10° of vision. The earliest signs of HCQ retinopathy on a central visual field may present as a cluster of paracentral points with decreased sensitivity. These points may be only mildly depressed. Hydroxychloroquine retinopathy A review of imaging. Hydroxychloroquine retinopathy screening. New Guidelines for Hydroxychloroquine Visual Screening. The American Academy of Ophthalmology released an updated set of screening recommendations for hydroxychloroquine Plaquenil and chloroquine to account for the many studies that have shown the effects of these medications on the retina 1. It succinctly makes the case for screening, and Hydroxychloroquine HCQ, sold under the brand name Plaquenil among others, is a medication used for the prevention and treatment of certain types of malaria. Specifically it is used for chloroquine-sensitive malaria. Other uses include treatment of rheumatoid arthritis, lupus, and porphyria cutanea tarda. It is taken by mouth. AAO revised guidelines. The AAO published dosing and screening recommendations for chloroquine and hydroxychloroquine in 2016, revising previous recommendations published in 2011. The current maximum daily HCQ dose recommended by the AAO is 5 mg/kg of real weight.